Tag Archives: Dr. Riccardo Lencioni

AstraZeneca’s Imfinzi Combination Therapy Shows Promise in Phase III Trial for Liver Cancer Treatment

(IN BRIEF) AstraZeneca has reported positive high-level results from the EMERALD-1 Phase III trial, demonstrating that its drug Imfinzi (durvalumab), in combination with transarterial chemoembolisation (TACE) and bevacizumab, significantly improves progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC) eligible … Read the full press release